ABSTRACT
Lavipharm, East Windsor, New Jersey, U.S.A. and Separex 5, Champigneulles, France
Although very important research and development (R&D) means are dedicated to applications of supercritical fluids (SCFs) in the pharmaceutical industry, a very limited number of commercial plants are now operating or under construction and few companies have acquired some know-how in process scale-up, especially in SCF formulation and particle design, in compliance with the constraints imposed in this industry [traceability and Good Manufacturing Processes (GMP), sterility, etc].
